GlassScriptPhysician profile
Rachel Thomas
NPI 1457121022
$567.71
in general payments reported to CMS, 2019-2025
14 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $284 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $147.95 | 2024-2025 | |
| Organon LLC | $61.12 | 2024 | |
| Hologic Sales and Service, LLC | $59.35 | 2024-2025 | Thinprep 2000 Processor, Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biogen, INC. | $53.06 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $41.87 | 2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $34.06 | 2025 | |
| American Regent | $31.67 | 2025 | Injectafer |
| Millicent US INC | $24.62 | 2024 | Intrarosa |
| Shield Therapeutics INC | $22.76 | 2024 | |
| Daiichi Sankyo INC. | $21.64 | 2025 | Injectafer |
| Pacira Pharmaceuticals Incorporated | $21.02 | 2024 | Exparel |
| Agile Therapeutics, INC. | $18.95 | 2024 | Twirla |
| Abbvie INC. | $15.57 | 2024 | |
| Exeltis, USA INC. | $14.07 | 2025 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.